-
SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer
•
SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted a pre-licensing application for the import of Orserdu (elacestrant) in Macau, seeking approval for its use in treating advanced or metastatic breast cancer. Elacestrant, a next-generation selective estrogen receptor degrader (SERD) developed by Eisai (TYO:…
-
China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy
•
The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing of the Elderly,” outlining 26 initiatives aimed at enhancing the quality of life for the aging population through improved livelihood, product supply, industrial growth, and security measures. Key recommendations include the optimization of elderly health…
-
China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to acquire a 63% stake in Chongqing Duoputai Pharmaceutical Co., Ltd for RMB 442 million (approximately USD 62 million). This acquisition will elevate CGP Pharma’s ownership in Duoputai to 90%, granting the company full control over…
-
Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure
•
Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase II clinical trial of its adeno-associated virus (AAV) therapy AB-1002 targeting congestive heart failure (CHF). This placebo-controlled study aims to assess the safety and efficacy of intracoronary infusion in 90 to 150 adults with non-ischemic…
-
CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine
•
CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of its first patient in a Phase I clinical study for its recombinant polio vaccine in Australia. This candidate vaccine is a non-infectious virus-like particle (VLP) formulation, developed utilizing CanSino’s proprietary protein structure design and VLP…
-
Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline
•
Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout from Merck that specializes in targeting interleukin-15 (IL-15). Under the terms of the deal, Calypso will receive an upfront payment of USD 250 million, along with potential milestone payments totaling up to USD 175 million.…
-
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
•
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big Pharma companies keen on its promising pipeline in cardiovascular and neuromuscular diseases. Sources indicate that Novartis (NYSE: NVS) was initially leading the charge against competitors AstraZeneca (AZ, NASDAQ: AZN) and Johnson & Johnson (J&J, NYSE:…
-
RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer
•
China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from the US FDA for its pipeline candidate RC88, a mesothelin (MSLN)-targeted antibody-drug conjugate (ADC). This designation recognizes RC88’s potential as a treatment for platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. Developed in-house,…
